Windlas Biotech Limited (WINDLAS)
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Q1FY27 results:
Standalone:
Revenue 2.48bn +18.1% y-y (2.10bn)
EBITDA 229.36m +(-) y-y (232.58m)
PAT 176.53m -0.07% y-y (176.65m)
- Profit before tax improved to 229.36m vs 201.62m last quarter
- EPS at 8.46 Rs basic, 8.32 Rs diluted for Q1FY27
- Board approved dividend of Rs 6.30 per share for FY26 paid on 31-Jul-2026
- Subsidiary Windlas Inc. dissolved effective 31-Mar-2026; no consolidated results from Q1FY27
- Buyback of 470,000 shares completed at Rs 1000 each; capital redemption reserve created
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 WINDLAS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add WINDLAS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Windlas Biotech Limited
Important.
The summary above is generated automatically from Windlas Biotech Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.